Specifically, we identified a significantly elevated transcript level of CD101 in low-grade glioma (LGG), glioblastoma (GBM), and all gliomas in comparison with that of the normal brain tissues (Figure 1B). This evidence concerns the gene CD101 and central nervous system cancer.